AstraZeneca has successfully been striking deals at an industry-leading rate over the past five years, with a concerted surge in both out-licensing and in-licensing work, according to a new report, Pharma Licensing Trends, 2014–18.
Analysts Datamonitor Healthcare put AstraZeneca comfortably ahead of other pharmaceutical firms, recognising the company as the most active dealmaker between 2014 and 2018, during which time it also signed the sector’s largest single deal.
Image: https://www.astrazeneca.com